Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-0525 in HER2-Overexpressing Solid Tumors
NCT06254807Phase 1Active, not recruiting
- Sponsor
- Carisma Therapeutics
- Start
- Jan 2024
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-0525 in solid tumor, sponsored by Carisma Therapeutics. Primary endpoints: Frequency and severity of adverse events at Day 28 and Feasibility of manufacturing CT-0525. Started Jan 2024; status: active, not recruiting.
02
Drugs
CT-0525
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06254807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254807.